Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M127,509Revenue (TTM) $M22,991Net Margin (%)33.6Altman Z-Score2.8
Enterprise Value $M124,020EPS (TTM) $10.3Operating Margin %42.6Piotroski F-Score8
P/E(ttm)16.6Beneish M-Score-2.6Pre-tax Margin (%)39.8Higher ROA y-yY
Price/Book4.110-y EBITDA Growth Rate %10.6Quick Ratio3.9Cash flow > EarningsY
Price/Sales5.65-y EBITDA Growth Rate %23.0Current Ratio4.1Lower Leverage y-yY
Price/Free Cash Flow13.5y-y EBITDA Growth Rate %17.1ROA % (ttm)10.2Higher Current Ratio y-yN
Dividend Yield %2.4PEG0.7ROE % (ttm)26.1Less Shares Outstanding y-yY
Payout Ratio %39.0Shares Outstanding M736ROIC % (ttm)29.6Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AMGN is held by these investors:



AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.59-0.74view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.1212.44view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.999.68view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.2110.23view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.4818.3view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.8412.64view
Hassan FredDirector 2015-08-19Buy3,010$166.634view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-3.94view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.0610.33view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.879.77view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Daniel Loeb Drops Pharma, Picks Up Rate-Sensitive Financials Feb 13 2017 
    GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
    How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
    Daniel Loeb's Third Point Hedge Fund 4th Quarter Commentary Feb 02 2017 
    Calendar 4th Quarter Shareholder Letter From Marty Whitman's Third Avenue Value Fund Feb 01 2017 
    6 Stocks Trading Below Peter Lynch Value Jan 26 2017 
    AbbVie Increases Price of Humira Jan 23 2017 
    Boehringer Ingelheim's Humira Biosimilar Under Review by EMA and FDA Jan 19 2017 
    Mean Reversion and the Bell Curve Jan 03 2017 
    Amgen: Opportunity May Be Knocking Dec 31 2016 

    More From Other Websites
    Roche Sues Amgen Over Avastin Biosimilar Drug Feb 20 2017
    Repatha Represents a Solid Growth Opportunity for Amgen in 2017 Feb 20 2017
    Amgen’s Neutropenia Drugs May See Falling Revenues in 2017 Feb 20 2017
    Enbrel Strengthens Its Position in Rheumatology and Dermatology Segments Feb 20 2017
    AMGEN INC Financials Feb 18 2017
    Mylan's Proposed Biosimailar for Cancer Under Review in U.S. Feb 17 2017
    Amgen Is Managing the Life Cycle of Its Mature Nephrology Drugs in 2017 Feb 17 2017
    Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
    Prolia Expected to Be a Significant Growth Driver for Amgen in 2017 Feb 17 2017
    Amgen Commits to Reaching Its Long-Term Financial Targets in 2018 Feb 16 2017
    Amgen Estimates Modest Revenue Performance in 2017 Feb 16 2017
    Health Care ETF Has Been Ailing Feb 16 2017
    Cramer fires back at naysayers: Here's your proof that th... Feb 15 2017
    Proof the rally is real Feb 15 2017
    Biotech boom? Feb 15 2017
    Amgen Applies for Leukemia Drug Label Expansion Feb 15 2017
    Amgen Looking to Broaden Leukemia Drug Blincyto's Label Feb 15 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)